Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 12;14(1):405–411. doi: 10.1111/cts.12893

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Kaplan–Meier survival curves for all patients with relapsed/refractory extranodal natural killer/T‑cell lymphoma, nasal type (ENKL) treated with cisplatin, dexamethasone, gemcitabine, and pegaspargase (DDGP) or methotrexate, dexamethasone, ifosfamide, L‐asparaginase, and etoposide (SMILE) regimen. (a) Progression‐free survival (PFS) is shown for all patients, showing that the DDGP group has a better PFS than the SMILE group (P = 0.008). (b) Overall survival (OS) is shown for all patients, showing that the DDGP group has a better OS than the SMILE group (P = 0.023).